M1 receptor activation is a requirement for arecoline analgesia

Farmaco. 2001 May-Jul;56(5-7):383-5. doi: 10.1016/s0014-827x(01)01091-6.

Abstract

Arecoline. a drug obtained from the Areca Catechu L., induced a dose-dependent antinociception (0.3-1 mg kg(-1) i.p.) which was prevented by the muscarinic antagonists pirenzepine (0.1 microg per mouse i.c.v.) and S-(-)-ET-126 (0.01 microg per mouse i.c.v.). A dose-dependent inhibition of the antinociception induced by arecoline was observed after inactivation of the M1 gene by an antisense oligodeoxyribonucleotide (aODN). This effect was detected 24 h after the last i.c.v. injection of aODN. These results indicate that arecoline antinociception is mediated by the activation of central M1 muscarinic receptors.

MeSH terms

  • Analgesics, Non-Narcotic / pharmacology*
  • Animals
  • Arecoline / pharmacology*
  • Injections, Intraperitoneal
  • Injections, Intraventricular
  • Male
  • Mice
  • Muscarinic Agonists / pharmacology*
  • Muscarinic Antagonists / pharmacology
  • Oligonucleotides, Antisense / pharmacology
  • Phenylacetates / pharmacology
  • Piperidines / pharmacology
  • Pirenzepine / pharmacology
  • Rats
  • Reaction Time / drug effects
  • Receptor, Muscarinic M1
  • Receptors, Muscarinic / drug effects*

Substances

  • Analgesics, Non-Narcotic
  • ET 126
  • Muscarinic Agonists
  • Muscarinic Antagonists
  • Oligonucleotides, Antisense
  • Phenylacetates
  • Piperidines
  • Receptor, Muscarinic M1
  • Receptors, Muscarinic
  • Pirenzepine
  • Arecoline